CVE-2026-32917 | OpenClaw before 2026.3.13 contains a remote command injection vulnerability in the iMessage attachment staging flow that allows attackers to execute arbitrary commands on configured remote hosts. The vulnerability exists because unsanitized remote attachment paths containing shell metacharacters are passed directly to the SCP remote operand without validation, enabling command execution when remote attachment staging is enabled.
OpenClaw before 2026.3.13 contains a remote command injection vulnerability in the iMessage attachment staging flow that allows attackers to execute arbitrary commands on configured remote hosts. The vulnerability exists because unsanitized remote attachment paths containing shell metacharacters are passed directly to the SCP remote operand without validation, enabling command execution when remote attachment staging is enabled.
```Code``` unterstützt. Zero-Day & Vulnerability Intelligence Hub
Echtzeit-Tracking mit EPSS Exploit-Wahrscheinlichkeiten, Angriffsvektor-Decodern und KI-Patch-Anleitungen.
📊 Historien-Charts — Criticals-Trend · Vendors · EPSS-Verteilung
| Tier | 2026-09-17 | 2026-09-30 |
|---|---|---|
| ≥90 % | 0 | 392 |
| ≥50 % | 0 | 1149 |
| ≥10 % | 0 | 2 |
| <10 % | 300 | 424 |
CVE-2026-32917 | OpenClaw before 2026.3.13 contains a remote command injection vulnerability in the iMessage attachment staging flow that allows attackers to execute arbitrary commands on configured remote hosts. The vulnerability exists because unsanitized remote attachment paths containing shell metacharacters are passed directly to the SCP remote operand without validation, enabling command execution when remote attachment staging is enabled.
OpenClaw before 2026.3.13 contains a remote command injection vulnerability in the iMessage attachment staging flow that allows attackers to execute arbitrary commands on configured remote hosts. The vulnerability exists because unsanitized
Noch keine Analyse zu CVE-2026-32917
Sei der Erste: Einschätzung, Betroffenheit, Workaround oder PoC — mit Antworten im Thread.